(Q47841114)

English

Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

Leishmania major

0 references

object named as

Ifeoma Okwor

1

0 references

3

object named as

Jude Uzonna

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

author name string

Dong Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

language of work or name

0 references

publication date

10 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

27

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

19

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

2554-2562

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

Focus: Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Leishmaniasis: current situation and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Leishmania: risk to the blood supply

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

The regulation of immunity to Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Leishmaniasis: current status of vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

IL-12 as an adjuvant for cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

The immunology of susceptibility and resistance to Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Development and regulation of cell-mediated immunity in experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Immunologic memory in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Development of a safe live Leishmania vaccine line by gene replacement.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Persistence without pathology in phosphoglycan-deficient Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

The role of CpG dinucleotides in DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

CpG-DNA protects against a lethal orthopoxvirus infection in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Antigen presentation by macrophages harboring intravesicular pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

IL-12 is dispensable for innate and adaptive immunity against low doses of Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

based on heuristic

inferred from DOI database lookup

Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.133

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.01.133

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/19428861

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47841114&oldid=2172525450"